Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
about
Hyperphosphatemia Management in Patients with Chronic Kidney DiseaseThe molecular mechanisms of hemodialysis vascular access failureVitamin D deficiency plays an important role in cardiac disease and affects patient outcome: Still a myth or a fact that needs exploration?Vitamin D, calcium, and atherosclerotic risk: evidence from serum levels and supplementation studiesComparison of classical and non-classical cardiovascular risk factors influencing the patency of native arteriovenous fistulas after percutaneous transluminal angioplasty therapy among haemodialysis patientsRegulation of bone remodeling: impact of novel therapies.Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.The association of adiposity with parathyroid hormone in healthy older adultsCalpain 1 inhibitor BDA-410 ameliorates α-klotho-deficiency phenotypes resembling human aging-related syndromes.Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.Predicting hospital cost in CKD patients through blood chemistry valuesParathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study.Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients.Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis.Is vitamin D deficiency a risk factor for ischemic heart disease in patients with established cardiovascular disease? 10-year follow-up of the Nova Scotia Health Survey.Changes in the calcium-parathyroid hormone-vitamin d axis and prognosis for critically ill patients: a prospective observational study.Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative.The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysisRacial differences in markers of mineral metabolism in advanced chronic kidney disease.The Risk of Peripheral Arterial Disease after Parathyroidectomy in Patients with End-Stage Renal Disease.Cardiovascular complications of pediatric chronic kidney disease.Reduced Stroke Risk After Parathyroidectomy in End-Stage Renal Disease: A 13-Year Population-Based Cohort Study.Putting cardiovascular disease and vitamin D insufficiency into perspective.The consequences of chronic kidney disease on bone metabolism and growth in children.Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes.Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidismA bimodal association of vitamin D levels and vascular disease in children on dialysisDynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantationThe potential for vitamin D receptor activation in cardiovascular research.Aortic Arch Calcification Predicts Patency Loss of Arteriovenous Fistula in End-Stage Renal Disease PatientsRole of vitamin d in cardiometabolic diseasesSignificant correlation between ankle-brachial index and vascular access failure in hemodialysis patientsLong-term outcome of chronic dialysis in children.Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismRelationship between vitamin D deficiency and cardiovascular disease.Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HClThe association between parathyroid hormone and mortality in dialysis patients is modified by wasting.Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufageninEffect of vitamin D deficiency on the development of postoperative atrial fibrillation in coronary artery bypass patients.
P2860
Q26743842-2AD69F0E-E692-4E20-BD48-7D0535F8C341Q26775058-0D33FEE8-5D93-4CEF-92A6-0FCB24F01899Q26777798-32B7172D-25B7-4D17-82F6-125855617C19Q26991851-F31D02EB-72E9-4D51-8E0B-1A829FAC11A9Q28219151-A56C75FB-BBCC-4543-9E8A-3FFF6614F873Q32029051-C0969C67-32F7-42C7-9D91-794F7D3B48B1Q33863759-30F48248-77CF-4D07-BAF5-E228D3BBCF1AQ33904929-72AB72C4-4886-4B09-B36D-3829CD447C60Q33986838-AF68E680-5C7E-4CE0-8DAD-3EC5F6112560Q34037021-40840FAD-BD96-48D6-A2E0-10B60E02C127Q34088691-EFAAF48D-16F7-480E-837D-39B303424528Q34113342-B6218C86-A2B4-43B2-9F21-288CDFF08F42Q34123786-1CED4577-7AE6-4920-8C68-2ABE91C2E356Q34610602-42EA5220-D84B-42F8-B1FC-18D9414FF638Q34842659-EB74CE34-95E3-4825-8A0C-04340049DCA4Q35000882-FBEEA750-A70C-422B-9A27-B87BF808CF1BQ35001969-A00DA9B3-CBD4-48D8-BFE6-A2BF7180C4F3Q35826159-6EA2B2C7-2659-4D40-8281-F185A67967C4Q35860700-6EBF8799-7490-4F5B-A286-B82C363F8DB3Q36047996-0AA6FF32-5611-4ED6-BAEA-D430CD78C63EQ36178721-007742DC-46AF-40C0-8242-C0732A757B67Q36194208-86298E02-3EFA-4BC8-BE6B-5697CB2489E5Q36273545-70095684-AD5D-4725-BB9C-A5E16C620368Q36318290-FE59E52C-A7AF-477C-AF1F-490712123893Q36371052-4F0A6C8B-D8DF-4223-8B72-5645ADFFDA9BQ36566674-8FE0C92B-C819-427F-84B9-27274C2115BBQ36666922-4A14C8B1-C8AC-4BCF-B06C-79542C09C398Q36677652-E6921C69-684A-4DF0-BAC4-1394161B2437Q36686934-9263E274-D938-43DE-A0E2-E0880B604CD4Q36763989-C06A222B-DAB4-4EE2-8A18-9B82E5D23163Q36823967-C440A4C4-B02A-486F-900D-E849A2C8D86FQ36825786-34450143-00AD-41FB-99D8-25FE2D7209A4Q37042120-37E863DC-BB9A-495A-956C-28E1821FF090Q37063372-C9D4B7E4-CBF3-4FCD-AD75-7E66B6BA74EEQ37102086-8094E942-1F69-4411-B712-A4B48E81F57CQ37199603-96BC4990-8756-4CAB-8F5D-0C574EBB4237Q37330326-C0267521-6E76-455D-A6D0-78BF5EA20D80Q37354867-DB4A350C-1F3A-405A-8B04-DA79FEBF0606Q37438192-9581BD76-00A6-4010-8BED-796B74BE8C2BQ37637916-75970E84-E726-47B5-9AC2-44364008DEFE
P2860
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
@ast
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
@en
type
label
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
@ast
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
@en
prefLabel
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
@ast
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure.
@en
P921
P1433
P1476
Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure
@en
P2093
S G Rostand
P304
P356
10.1046/J.1523-1755.1999.00575.X
P407
P577
1999-08-01T00:00:00Z
P5875
P6179
1052330202